No Data
No Data
No Data
No Data
No Data
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
TipRanksApr 26 15:08
Quest Diagnostics: A Hold Rating Amid Solid Earnings and Strategic Caution
TipRanksApr 26 14:15
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight
Yahoo FinanceApr 26 13:05
Quest Diagnostics Is Maintained at Equal-Weight by Barclays
Quest Diagnostics Is Maintained at Equal-Weight by Barclays
Dow JonesApr 26 02:47
Barclays: Maintaining the Quest Diagnostics (DGX.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $138.00 to $144.00.
Barclays: Maintaining the Quest Diagnostics (DGX.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $138.00 to $144.00.
Zhitong FinanceApr 26 02:40
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $144
Barclays analyst Stephanie Davis maintains Quest Diagnostics with a Equal-Weight and raises the price target from $138 to $144.
Analyst UpgradesApr 26 02:36
No Data
No Data